What is XBiotech?
XBiotech is a fully integrated global biosciences company focused on the discovery, development, and commercialization of therapeutic antibodies. Leveraging its proprietary True Human technology, the company is advancing a pipeline of antibody therapies aimed at transforming care in oncology, inflammatory diseases, and infectious diseases. Headquartered in Austin, Texas, XBiotech also possesses advanced biotech manufacturing technology, enabling rapid and cost-effective production of its True Human Antibodies.
How much funding has XBiotech raised?
XBiotech has raised a total of $76M across 1 funding round:
Stock Offering
$76M
Stock Issuance/Offering (2015): $76M, investors not publicly disclosed
What's next for XBiotech?
The substantial enterprise-level funding and recent strategic investment position XBiotech for accelerated growth and pipeline expansion. This capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and support the commercialization of its novel antibody therapies. The company's focus on redefining standards of care in critical disease areas suggests a strategic trajectory towards significant market impact and potential therapeutic breakthroughs.
See full XBiotech company page
